Lack of progress in cardiogenic shock: lessons from the GUSTO trials
被引:38
作者:
Menon, V
论文数: 0引用数: 0
h-index: 0
机构:
Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USAColumbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Menon, V
[1
]
Hochman, JS
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Hochman, JS
Stebbins, A
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Stebbins, A
Pfisterer, M
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Pfisterer, M
Col, J
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Col, J
Anderson, RD
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Anderson, RD
Hasdai, D
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Hasdai, D
Holmes, DR
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Holmes, DR
Bates, ER
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Bates, ER
Topol, EJ
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Topol, EJ
Califf, RM
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Califf, RM
Ohman, EM
论文数: 0引用数: 0
h-index: 0
机构:Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
Ohman, EM
机构:
[1] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Cardiac Study Ctr, Div Cardiol, New York, NY 10025 USA
[2] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA
[3] Univ Basel Hosp, Div Cardiol, CH-4031 Basel, Switzerland
[4] Clin Univ, Div Cardiol, Brussels, Belgium
[5] Mayo Clin, Div Cardiol, Rochester, MN USA
[6] Univ Michigan, Med Ctr, Div Cardiol, Ann Arbor, MI 48109 USA
[7] Cleveland Clin Fdn, Div Cardiol, Cleveland, OH 44195 USA
Aims We used the GUSTO-I and GUSTO-III databases to evaluate our performance in treating cardiogenic shock patients over much of the 1990s. Methods and Results GUSTO-I (1990-1993) and GUSTO-III (1995-1997) prospectively identified all patients with cardiogenic shock complicating acute myocardial infarction. Demographics, clinical presentation and outcomes for cardiogenic shock patients in the two trials were compared. Only patients enrolled with cardiogenic shock in countries common to both trials were included in these analysis. The 695 patients with cardiogenic shock in GUSTO-III were compared with the 2814 patients with cardiogenic shock in GUSTO-I. GUSTO-III patients were older (P=0.0001) and more likely to be diabetic (P=0.009) and hypertensive (P=0.025). They had a higher Killip class (P=0.002) and significantly greater index anterior infarction than cardiogenic shock patients enrolled in GUSTO-I. Time to treatment, presentation heart rate. and diastolic blood pressure were similar: however, systolic brood pressure at presentation was higher among GUSTO-III patients (P=0.002). Rates of coronary angiography, pulmonary artery catheterization, and mechanical ventilation declined in GUSTO-III compared with GUSTO-I (P=0.001); rates of angioplasty and bypass surgery were similar. Cardiogenic shock mortality in GUSTO-III was significantly higher than in GUSTO-I (62 vs 54%, P=0.001), as were rates of reinfarction (14 vs 11%, P=0.013) and recurrent ischaemia (35 vs 27%, P=0.00001). Mortality at non-U.S. sites (68 and 64%) was higher than at U.S. sites (53 and 50%) in both GUSTO-I and GUSTO-III studies, respectively. Angioplasty, bypass surgery, and balloon pump rates were lower for non-U.S. patients. Conclusions Cardiogenic shock continues to be associated with high mortality in thrombolytic-treated patients. Lower mortality observed in the U.S.A, supports consideration for percutaneous and surgical revascularization. (C) 2000 The European Society of Cardiology.